Molecular markers of hemostatic activation and inflammation following major injury: Effect of therapy with IFN-γ

Journal of Interferon and Cytokine Research

Volumn 18, Issue 5, 1998, Pages 327-335

  Dries, David J ^a   Walenga, Jeanine M ^b   Hoppensteadt, Debra ^b   Fareed, Jawed ^b  

^a Department of Surgery   (United States)

^b LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBIN; INTERLEUKIN 6; PLACEBO; RECOMBINANT GAMMA INTERFERON; THROMBIN; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; BLOOD CLOTTING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; FIBRINOLYSIS; HEMOSTASIS; HUMAN; IMMUNOTHERAPY; INFLAMMATION; INJURY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE TRAUMA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME;

EID: 0031979519     PISSN: 10799907     EISSN: None     Source Type: Journal    
DOI: 10.1089/jir.1998.18.327     Document Type: Article

References (40)

1. Update: YPLL before age 65: US, 1988 and 1989. (1991). MMWR 40, 60-62.
2. GORIS, R.J.A., and DRAAISMA, J. (1982). Causes of death after blunt trauma. J. Trauma 22, 141-146.
3. BAKER, C.C., OPPENHEIMER, L., STEPHENS, B., LEWIS, F.R., and TRUNKEY, D.D. (1980). Epidemiology of trauma deaths. Am. J. Surg. 140, 144-150.
4. POLK, H.C., Jr., CHEADLE, W.G., LIVINGSTON, D.H., RODRIQUEZ, J.L., STARKO, K.M., IZU, A.B., JAFFE, U.S., and SONNENFELD, G. (1992). A randomized prospective clinical trial to determine the efficacy of interferon-γ in severely injured patients. Am. J. Surg. 163, 191-196.
5. DRIES, D.J., JURKOVICH, G.J., MAIER, R.V., CLEMMER, T.P., STRUVE, S.N., WEIGELT, J.A., STANFERD, G.G., HERR, D.L., CHAMPION, H.R., LEWIS, F.R., HOYT, D., HANSBROUGH, J., YELLIN, A.E., BERNE, T.V., TRUNKEY, D.D., JAFFE, H.S., MUNERA, C., FISHER, P., and STARKO, K.M. (1994). Effect of interferon-γ on infection-related death in patients with severe injuries. Arch. Surg. 129, 1031-1041.
6. FAIST, E., MEWES, A., STRASSER, T., WALZ, A., ALKAN, S., BAKER, C., ERTEL, W., and HEBERER, G. (1988). Alteration of monocyte function following major injury. Arch. Surg. 123, 287-292.
7. 2 production in severely injured patients. Arch. Surg. 123, 293-299.
8. HERSHMAN, M.J., CHEADLE, W.G., KUFTINEC, D., POLK, H.C., Jr., and GEORGE, C.D. (1988). An outcome predictive score for sepsis and death following injury. Injury 19, 263-266.
9. LIVINGSTON, D.H., APPEL, S.H., WELLHAUSEN, S.R., SONNENFELD, G., and POLK, H.C., Jr. (1988). Depressed interferon-gamma production and monocyte HLA-DR expression after severe injury. Arch. Surg. 123, 1309-1312.
10. BROWNING, J.L., and RIBOLINI, A. (1987). Interferon blocks interleukin-1 induced prostaglandin release from human peripheral monocytes. J. Immunol. 138, 2857-2863.
11. MALUISH, A.E., URBA, W.J., LONGO, D.L., OVERTON, W.R., CEGGIN, D., CRISP, E.R., WILLIAMS, R., SHERWIN, S.A., GORDON, K., and STEIS, R.G. (1988). The determination of an immunologically active dose of interferon-gamma in patients with melanoma. J. Clin. Oncol. 6, 434-445.
12. PETRONI, K.C., SHEN, L., and GUYRE, P.M. (1988). Modulation of human polymorphonuclear leukocyte IgG Fc receptors and Fc receptor-mediated functions by IFN-γ and glucocorticoids. J. Immunol. 140, 3467-3472.
13. PERUSSIA, B., KOBAYASHI, M., ROSSI, M.E., AREGON, I., and TRIMCHIERI, G. (1987). Immune interferon enhances functional properties of human granulocyte-macrophage colony-stimulating factor. J. Immunol. 138, 765-774.
14. THE INTERNATIONAL CHRONIC GRANULOMATOUS DISEASE COOPERATIVE STUDY GROUP. (1991). A controlled trial of interferon-gamma to prevent infection in chronic granulomatous disease. N. Engl. J. Med. 324, 509-516.
15. KAPLAN, G. (1993). Recent advances in cytokine therapy in leprosy. J. Infect. Dis. 167, (Suppl 1), S18-S22.
16. SAMPAIO, E.P., MOREIRA, A.L., SARNO, E.N., MALTA, A.M., and KAPLAN, G. (1992). Prolonged treatment with recombinant interferon-γ induces erythema nodosum leprosum in lepromatous leprosy patients. J. Exp. Med. 175, 1729-1737.
17. SAMPAIO, E.P., SARNO, E.N., GALILLY, R., COHN, Z.A., and KAPLAN, G. (1991). Thalidomide selectively inhibits tumor necrosis factor-α production by stimulated human monocytes. J. Exp. Med. 173, 699-703.
18. BEUTLER, B., and CERAMI, A. (1987). Cachectin: more than a tumor necrosis factor. N. Engl. J. Med. 316, 379-385.
19. TRACEY, K.J., VLASSARA, H., and CERAMI, A. (1989). Cachectin/tumor necrosis factor. Lancet 1, 1122-1126.
20. NAWROTH, P.P., and STERN, D.M. (1986). Modulation of endothelial cell hemostatic properties by tumor necrosis factor. J. Exp. Med. 163, 740-745.
21. CONWAY, E.M., BACH, R., ROSENBERG, R.D., and KONIGSBERG, W.H. (1989). Tumor necrosis factor enhances expression of tissue factor mRNA in endothelial cells. Thromb. Res. 53, 231-241.
22. VAN HINSBERGH, V.W., KOOISTRA, T., VAN DEN BERG, E.A., PRINCEN, A.M., FIERS, W., and EMEISS, J.J. (1988). Tumor necrosis factor increases the production of plasminogen activator inhibitor in human endothelial cells in vitro and in rats in vivo. Blood 72, 1467-1473.
23. TRACEY, K.J., LOWRY, S.F., FAHEY, T.J., III, ALBERT, J.D., FONG, Y., HESSE, D., BEUTLER, B., MANOGUE, K.R., CALVANO, S., WEI, H., CERAMI, A., and SHIRES, G.T. (1987). Cachectin/tumor necrosis factor induces lethal shock and stress hormone responses in the dog. Surg. Gynecol. Obstet. 164, 415-422.
24. GIRARDIN, E., GRAU, G.E., DAYER, J.-M., ROUX-LOMBARD, P., and LAMBERT, P.H. (1988). Tumor necrosis factor and interleukin-1 in the serum of children with severe infectious purpura. N. Engl. J. Med. 319, 397-400.
25. VAN DER POLL, T., BULLER, H.R., TEN CATE, H., WORTEL, C.H., BAUER, K.A., VAN DEVENTER, S.J., HACK, C.E., SAUERWEIN, H.P., ROSENBERG, R.D., and TEN CATE, J.W. (1990). Activation of coagulation after administration of tumor necrosis factor to normal subjects. N. Eng. J. Med. 322, 1622-1627.
26. MOCK, C., DRIES, D.J., JURKOVICH, G., and MAIER, R.V. (1996). Assessment of two clinical trials: interferon-gamma therapy in severely injured patients. Shock 5, 234-240.
27. MILES, R.H., PAXTON, T.P., DRIES, D.J., and GAMELLI, R.L. (1994). Interferon-gamma increases mortality following cecal ligation and puncture. J. Trauma 36, 607-611.
28. MILES, R.H., PAXTON, T.P., ZACHIES, D., DRIES, D., and GAMELLI, R.L. (1994). Systemic administration of interferon-gamma impairs wound healing. J. Surg. Res. 56, 288-294.
29. JURKOVICH, G.J., MILESKI, W.J., MAIER, R.V., WINN, R.K., and RICE, C.L. (1991). Interferon-gamma increases sensitivity to endotoxin. J. Surg. Res. 51, 197-203.
30. NATHAN, C.F., PRENDERGAST, T.J., WIEBE, A.U., STANLEY, E.R., PLATZER, E., REMHOLD, H.G., WELTE, K., RUBIN, B.Y., and MURRAY, H.W. (1984). Activation of human macrophages: comparison of other cytokines with interferon-gamma. J. Exp. Med. 160, 600-605.
31. LEITHAUSER, B., MATTHIAS, F.R., NICOLAI, U., and VOSS, R. (1996). Hemostatic abnormalities and the severity of illness in patients at the onset of clinically defined sepsis. Possible indication of the degree of endothelial cell activation? Intensive Care Med. 22, 631-636.
32. WALENGA, J.M., KOWAL-VERN, A., FAREED, J., and GAMELLI, R.L. (1992). Hemostasis in the trauma patient. In Trauma 2000: Strategies for the New Millennium. D.J. Dries and R.L. Gamelli (eds.) Austin, TX: RG Landes, pp. 167-178.
33. KOWAL-VERN, A., GAMELLI, R.L., WALENGA, J.M., HOPPENSTEADT, D., SHARP-PUCCI, M., and SCHUMACHER, H.R. (1992). The effect of burn wound size on hemostasis: a correlation of the hemostatic changes to the clinical state. J. Trauma 33, 50-57.
34. GANDO, S., KAMEUE, T., NANZAKI, S., HAYAKAWA, T., and NAKANISHI, Y. (1997). Participation of tissue factor and thrombin in posttraumatic systemic inflammatory syndrome. Crit. Care Med. 25, 1820-1826.
35. ENGELMAN, D.T., GABRAM, S.G.A., ALLEN, L., ENS, G.E., and JACOBS, L.M. (1996). Hypercoagulability following multiple trauma. World J. Surg. 20, 5-10.
36. BOLDT, J., WOLLBRUCK, T., SONNEBORN, S., WELTERS, A., and HEMPELMANN, G. (1995). Thrombomodulin in intensive care patients. Intensive Care Med. 21, 645-650.
37. LAMPL, L., HELM, M., SPECHT, A., BOCK, K.H., HARTEL, W., and SEIFRIED, E. (1994). Blood coagulation parameters as prognostic factors in multiple trauma: can clinical values be an early diagnostic aid? Zentralbl. Chir. 119, 683-689.
38. ABILDGAARD, U. (1995). Relative roles of tissue factor pathway inhibitor and antithrombin in the control of thrombogenesis. Blood Coag. Fibrinol. 6, S45-S49.
39. ALBRECHT, S., MULLER, S., SEIGERT, G., LUTHER, T., and MULLER; M. (1995). Plasma concentration of tissue factor and factor VII in patients after abdominal surgery. Thromb. Res. 77, 557-562.
40. LINDAHL, A.K., ABILDGAARD, U., and STAALESEN, R. (1991). The anticoagulant effect in heparinized blood and plasma resulting from interactions with extrinsic pathway inhibitor. Thromb. Res. 64, 155-168.